Population Health Research Institute
Study List

ACCORD (Completed)
Action to Control CardiOvascular Risk in Diabetes
Main Trial coordination by NIH; PHRI coordinates the Canadian network and has significant input in the protocol development and trial conduct

< back


To open a new browser window and visit the ACCORD website, please click here.


The ACCORD trial tests treatment strategies aimed at reducing cardiovascular events in type 2 diabetes. The trial is designed to test the effects of major CVD events of intensive glycemia control, of treatment to increase HDL-cholesterol and lower triglycerides     (in the context of good LDL-c and glycemias control), and of intensive blood pressure control (in the context of good glycemia control).  On February 6 2008 the intensive arm of ACCORD was stopped and all intensive glycemia  participants were "transitioned" to the standard glycemia arm of the trial due to an increase in mortality.  All other arms continued as per protocol. 

Study Design: Randomized Multicenter Double 2X2 Factorial Design.

Intervention: Intensive Glycemia Control and Intensive Blood Pressure Control vs. Standard Care.

Length of Study: 9 years.

# of Patients: 10,251 (1,508 in Canada).

Patient Populations: Patients with type 2 diabetes mellitus.


Presentations

Available upon study completion.


Main Publications (for a full listing of PHRI publications, please visit the 'Media and Publications' section)

ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99(suppl):21i-33i.

 Bonds DE, Kurashige EM, Bergenstal R, Brillon D, Domanski M, Felicetta JV, Fonseca VA, Hall K, Hramriak I, Miller ME, Osei K, Simons-Morton DG, for the ACCORD Study Group. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99 (suppl):80i- 89i.
 Cukierman-Yaffe T, Gerstein HC, Williamson JD, Lazar RM, Lovato L, Miller ME, Coker LH, Murray A, Sullivan MD, Marcovina SM, Launer LJ, for the ACCORD Memory in Diabetes (MIND) Investigators. Relationship Between Baseline Glycemic Control and Cognitive Function in Individuals With Type 2 Diabetes and Other Cardiovascular Risk Factors. Diabetes Care, February 2009 32:221-226;
 Cushman WC, Grimm RH, Cutler JA, Evans GW, Capes S, Corson MA, Sadler LS, Alderman MH, Peterson K, Bertoni A, Basile JN, for the ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99(suppl):44i-55i.
 DIABETES CARE, VOLUME 28, NUMBER 3, MARCH 2005
Gerstein HC, Riddle MC, Kendall DM, Cohen RM, Goland R, Feinglos MN, Kirk JK, Hamilton BP, Ismail-Beigi F, Feeney P. for the ACCORD Study Group. Glycemia treatment strategies in the ACCORD trial. Am J Cardiol 2007;99(suppl):34i- 43i.
Ginsberg HN, Bonds DE, Lovato LC, Crouse JR, Elam MB, Linz PE, O'Connor PJ, Leiter LA, Weiss D, Lipkin E, Fleg JL, for the ACCORD Study Group. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99(suppl):56i- 67i.
Goff DC, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, Buse JB, Genuth S, Probstfield JL, Simons-Morton DG, for the ACCORD Study Group. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99(suppl):4i-20i.
Kingry C, Bastien A, Booth G, Geraci TS, Kirpach BR, Lovato LC, Margolis KL, Rosenberg Y, Sperl-Hillen JM, Vargo L, Williamson JD, Probstfield JL, for the ACCORD Study Group. Recruitment strategies in the Action to Control Cardiovascular Risk
Sullivan MD, Anderson RT, Aron D, Atkinson HH, Bastien A, Chen GJ, Feeney P, Gafni A, Hwang W, Katz LA, Narayan KMV, Nwachuku C, O'Connor PJ, Zhang P, for the ACCORD Study Group. Health-Related Quality of Life and Cost-Effectiveness Components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Rationale and Design Am J Cardiol 2007;99 (suppl):90i-102i.
Williamson JD, Miller ME, Bryan RN, Lazar RM, Coker LH, Johnson J, Cukierman T, Horowitz KR, Murray A, Launer LJ, for the ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): Rationale, Design, and Methods. Am J Cardiol 2007;99 (suppl):112i-122i).

 

 

Print    Email
Population Health Research Institute • Hamilton, Ontario • information@phri.ca